Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C - Wikidata - awgldk - TriplyDB

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C

http://www.wikidata.org/entity/Q34914880

about

Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic Effects Oxidative stress modulation in hepatitis C virus infected cells Natural Products as Tools for Defining How Cellular Metabolism Influences Cellular Immune and Inflammatory Function during Chronic Infection Silymarin for HCV infection Liver fibrosis and protection mechanisms action of medicinal plants targeting apoptosis of hepatocytes and hepatic stellate cells Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.Silymarin reduces profibrogenic cytokines and reverses hepatic fibrosis in chronic murine schistosomiasis.Physiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction.Complementary and alternative medications in hepatitis C infection.Potential treatment options and future research to increase hepatitis C virus treatment response rate Silybin and the liver: from basic research to clinical practice.Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking.Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.Antioxidants as therapeutic agents for liver disease.Rationale, challenges, and participants in a Phase II trial of a botanical product for chronic hepatitis C Understanding silibinin's modes of action against HCV using viral kinetic modeling Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection.Interaction of silymarin flavonolignans with organic anion-transporting polypeptides.Impact of oral silymarin on virus- and non-virus-specific T-cell responses in chronic hepatitis C infection Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinoma.An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.Silymarin induces insulin resistance through an increase of phosphatase and tensin homolog in Wistar rats.Hepatoprotective effect of silymarin.Antiviral therapy for hepatitis C virus: beyond the standard of care.Milk thistle and its derivative compounds: a review of opportunities for treatment of liver disease.Hepatitis C virus and natural compounds: a new antiviral approach?The toxicity and pathology of selected dietary herbal medicines.Review article: management of chronic hepatitis C in patients with contraindications to anti-viral therapy.The therapeutic potential of milk thistle in diabetes.Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis.Chemoprevention against hepatocellular carcinoma.Role of AMPK signaling in mediating the anticancer effects of silibinin in esophageal squamous cell carcinoma.Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years.Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV.Herbal medicine and liver disease, for any conclusion we need to do more studies.Effects of Silymarin, Glycyrrhizin, and Oxymatrine on the Pharmacokinetics of Ribavirin and Its Major Metabolite in Rats.Effects and tolerance of silymarin (milk thistle) in chronic hepatitis C virus infection patients: a meta-analysis of randomized controlled trials.

P2860

Q26741423-DF34555A-2F36-4D1A-8D00-366E91CB5263 Q26774003-0AA6C4C6-4D67-45D3-976D-9F9044D4BEB5 Q26775036-CC755D68-30D6-48ED-B7D0-7774494217A8 Q26851453-3144A9D9-8495-44F6-8809-575CACCB6E0B Q30369750-51405116-7AE7-48C2-9315-6B05B8CF50E7 Q30997889-D2FCF9D4-1353-49BE-BABA-801BE47A4F3F Q33622760-2ECA7F51-B504-4777-A62E-2EF17C90AF0F Q33702513-ED365296-DA28-4A3C-AEC5-F3659BB56EF9 Q34411345-6EC4FAE5-4182-4ABC-8CAD-8DDCE22EC7CE Q34576190-5268E535-7073-4B04-8EEE-23B6EA4672B3 Q34629765-42050038-9E01-488C-9DD7-BC3CC71BFBBE Q34652154-80A543B6-DD7D-40B3-86EF-D0445A556F1B Q35175904-E3B2225C-2A0A-4D93-A59B-77195704C280 Q35579547-982A36E2-93C9-47D7-9DF2-288D2879C880 Q35585469-8E36F0F2-BF43-4577-86DD-43771FA82799 Q35800747-151B3601-6CD0-416D-8ECA-197F9ED36445 Q35894929-70457019-4EDC-4A97-8535-181C0127E059 Q36672710-13959BAB-1E46-485B-8125-0FAEA4A85B16 Q36675737-980DE6B9-C52E-4080-98F2-57023AF5BE43 Q36776621-2421DECB-2493-40D9-956D-57892749FAEF Q36910728-6CABFC73-13C9-4E93-9D82-84F8A8A32709 Q36933129-27F4FA64-030B-40BF-907D-49A2CF5D2BED Q37399436-36BE42DE-1131-4D51-9352-B1A9868A4F97 Q37422723-94E834FC-B5B2-45A4-97D3-AC4F9016B5A2 Q37431571-2759084C-AFDF-4D02-B1A4-CA33C3FEA656 Q37646391-7F68B9BB-59A5-4D5C-B42E-B73DCEC3806A Q37945201-0A57F390-76DA-4A03-BD5E-B2FBB4EE859D Q38058825-48606026-8159-4F51-8879-D3A90A03E8EF Q38064280-E943764E-D02E-4FFA-B7E6-DFBF628EB098 Q38069420-1AA7A8FD-5620-481C-826B-B1A275FCA61D Q38166445-C8DFF5D8-DF96-4A64-A260-1B589D3A5C16 Q38268147-E1E2BDC4-3C55-440D-A298-427554482C19 Q38326327-26A8BC41-B63C-462A-8EC3-CF6D68583A36 Q38550165-D7B72C64-8467-4A73-B849-848663A36052 Q38819571-DAA370AB-34C0-4C02-A7D3-A45F1C166B85 Q39104518-2F8E859F-7886-469D-B187-852DE75DA5E5 Q39560356-9A6F0A73-5FDF-47E2-A764-DF5599B7DE6B Q40565173-4F8EE6AB-F5A4-4852-857E-9139A4992D2C Q40821539-8FA9BAC5-EB38-4607-A739-448BB49BB99D Q41729153-EC190C53-8394-458E-8448-401F5ED76C12

P2860

Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C

http://www.wikidata.org/entity/Q34914880

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@ast

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@en

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@nl

type

label

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@ast

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@en

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@nl

prefLabel

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@ast

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@en

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@nl

P1433

Q34914880-680B9D0B-7922-4E3B-BEB7-981F394A3E9E

P1476

Q34914880-B3E01322-B115-45AA-95B8-F603FAE95B85

P2093

Q34914880-2191A3A4-F6A4-4E04-B15A-D0E22F41F675

Q34914880-31D57CDB-BBF4-4434-81D0-C362128FA2EA

Q34914880-32584089-5E07-4201-B9F1-0A9E98420C22

Q34914880-45AD55A7-E9C1-4C78-9A0F-D7CDC68310C4

Q34914880-6253CE3B-72F6-4308-97BD-C4403C9BF25F

Q34914880-80218783-3384-43B9-9A7D-7B586CFCAAB8

Q34914880-9665A565-33DF-4F45-AE4E-B2D4CDD0F5F0

Q34914880-9C2A5DFA-E2CF-4E5F-BC44-B9CC288B2CE2

Q34914880-D409AC1D-1670-4FA1-9C0D-3B87BFE33B06

Q34914880-E5320AFB-4756-4AF6-94A7-244EBB92B3CA

P2860

Q34914880-3CD4027B-063E-4C66-B7EC-4A69D497F93F

Q34914880-420DECCC-CD15-466E-ADA3-BE27C0B3B0C9

Q34914880-5628E3AA-0DEF-474E-8D99-CE34599C990B

Q34914880-5BCA7B96-E596-4DF2-B8E1-E3CEDC965923

Q34914880-5BCE578F-68D1-4228-B9A7-EC3C0818741C

Q34914880-5C0A93A2-B979-4EB1-B0E1-04F70C669AFE

Q34914880-78227BEF-4101-4105-A125-1556C45BA12B

Q34914880-7A8E36DF-9FF4-4429-BDB3-E798D554CD8A

Q34914880-7FD9C87C-EF99-4A2F-8594-780C4F5342FA

Q34914880-8275864C-AA33-46C0-8F23-A173E872D693

P304

Q34914880-6BBCAB9F-8148-4324-9DB9-367F0FC7BBB0

P31

Q34914880-D560EE09-2ED4-489D-8150-3EB1DABE9358

P356

Q34914880-83F7C504-9AEC-47C9-B243-327D69ECC184

P433

Q34914880-4769559F-18C9-4506-ACD0-28EAC877E54B

P478

Q34914880-42960602-6D8B-4B9E-8AF7-B531EE7FAF60

P50

Q34914880-58F6A4D3-8C2E-4CDB-801D-44663CCF3DC1

Q34914880-79374FBA-D04C-459A-94C6-3A4545E7A8A1

Q34914880-DF14F961-0629-4AB7-9469-7ED56FE2EA76

P577

Q34914880-B261773B-5F42-4047-8B1A-2531A6875579

P5875

Q34914880-2E20FD92-93B7-4E30-88AE-A81FE23F6907

P698

Q34914880-29F80DA0-2992-428B-8E74-CCEC3D59AC01

P932

Q34914880-658C314D-CEAE-4D9B-990B-717B2A428667

P356

0091270009347475

P1433

The Journal of Clinical Pharmacology

P1476

Silymarin ascending multiple o ...... ients with chronic hepatitis C

@en

P2093

Edward Doo

http://www.w3.org/2001/XMLSchema#string

Josh Berman

http://www.w3.org/2001/XMLSchema#string

Michael W Fried

http://www.w3.org/2001/XMLSchema#string

Philip C Smith

http://www.w3.org/2001/XMLSchema#string

Qi-Ying Liu

http://www.w3.org/2001/XMLSchema#string

Roy L Hawke

http://www.w3.org/2001/XMLSchema#string

Sarah J Schrieber

http://www.w3.org/2001/XMLSchema#string

Steven H Belle

http://www.w3.org/2001/XMLSchema#string

SyNCH Trial Group

http://www.w3.org/2001/XMLSchema#string

Tedi A Soule

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey

Use of complementary and alternative medicine in patients with liver disease.

Treatment of chronic hepatitis C with PEGylated interferon and ribavirin.

Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.

Silymarin treatment of viral hepatitis: a systematic review.

Peginterferon and ribavirin for chronic hepatitis C.

Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).

Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results.

P304

434-449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270009347475

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P50

K. Rajender Reddy

P577

2009-10-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38022206

http://www.w3.org/2001/XMLSchema#string

P698

19841158

http://www.w3.org/2001/XMLSchema#string

P932

3086763

http://www.w3.org/2001/XMLSchema#string